CompletedPhase 2NCT05005728

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Studying Anorectal malformation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Xencor, Inc.
Principal Investigator
Jolene Shorr
Xencor, Inc.
Intervention
vudalimab + carboplatin + cabazitaxel(combination_product)
Enrollment
72 target
Eligibility
18 years · MALE
Timeline
20212025

Study locations (26)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05005728 on ClinicalTrials.gov

Other trials for Anorectal malformation

Additional recruiting or active studies for the same condition.

See all trials for Anorectal malformation

← Back to all trials